The patent dance laid out in the Biologics Price Competition and Innovation Act (BPCIA) is merely a temporary safe harbor that biosimilar sponsors may opt out of, a federal district judge ruled last week in denying Amgen Inc.'s request for a temporary injunction and partial summary judgment to halt the U.S. launch of Sandoz Inc.'s Zarxio, a biosimilar to Amgen's blockbuster Neupogen.